dc.contributor.author | García, Gregory Alfonso | spa |
dc.contributor.author | Mejía, Omar | spa |
dc.contributor.author | García Cardona, Ananías | spa |
dc.contributor.author | Clavijo Grimaldi, Dianney | spa |
dc.contributor.author | Muñoz, Jimmy | spa |
dc.contributor.author | Hernández, Sergio | spa |
dc.date.accessioned | 2020-10-27T14:21:21Z | |
dc.date.available | 2020-10-27T14:21:21Z | |
dc.date.issued | 2006-12-04 | |
dc.identifier.issn | 2382-4603 | |
dc.identifier.issn | 0123-7047 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12749/10373 | |
dc.description.abstract | El Factor Inhibidor de la Leucemia (LIF), es un mediador de comunicación celular con un amplio rango de actividades biológicas que incluyen diferenciación celular, crecimiento y proliferación celular, trofismo celular y efecto anti-apoptótico protección celular de diferentes tipos de células y tejidos, regulación del metabolismo energético y óseo, desarrollo neural, embriogénesis, reparación y remodelación tisular, modulación de la inflamación. Debido a sus actividades pleiotrópicas, es central en los eventos patológicos, relacionados a muchos desórdenes. En esta revisión se comentaran los diversos tópicos relacionados con esta citoquina. [García GA, Mejía O, García A, Clavijo D, Muñoz J, Hernández S. Factor Inhibidor de la Leucemia y su papel en procesos fisiológicos y patológicos. MedUNAB 2006 | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | spa | spa |
dc.publisher | Universidad Autónoma de Bucaramanga UNAB | |
dc.relation | https://revistas.unab.edu.co/index.php/medunab/article/view/140/125 | |
dc.relation.uri | https://revistas.unab.edu.co/index.php/medunab/article/view/140 | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.source | MedUNAB; Vol. 9 Núm. 3 (2006): Modulación PPARγ, Crisis Psicogénica, Rendimiento y estrés; 236-245 | |
dc.subject | Ciencias biomédicas | |
dc.subject | Ciencias de la vida | |
dc.subject | Innovaciones en salud | |
dc.subject | Investigaciones | |
dc.title | Factor inhibidor de la leucemia y su papel en procesos fisiológicos ó patológicos | spa |
dc.title.translated | Leukemia inhibitory factor and its role in physiological or pathological processes | eng |
dc.publisher.faculty | Facultad Ciencias de la Salud | spa |
dc.publisher.program | Pregrado Medicina | spa |
dc.type.driver | info:eu-repo/semantics/article | |
dc.type.local | Artículo | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | |
dc.subject.keywords | Health Sciences | eng |
dc.subject.keywords | Medicine | eng |
dc.subject.keywords | Medical Sciences | eng |
dc.subject.keywords | Biomedical Sciences | eng |
dc.subject.keywords | Life Sciences | eng |
dc.subject.keywords | Innovations in health | eng |
dc.subject.keywords | Research | eng |
dc.subject.keywords | Cancer | eng |
dc.subject.keywords | Cytokine | eng |
dc.subject.keywords | Embriology | eng |
dc.subject.keywords | Growth factor | eng |
dc.subject.keywords | Interleukin 6 | eng |
dc.subject.keywords | Infertility | eng |
dc.subject.keywords | Neurogenesis | eng |
dc.identifier.instname | instname:Universidad Autónoma de Bucaramanga UNAB | spa |
dc.type.hasversion | Info:eu-repo/semantics/publishedVersion | |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.relation.references | Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16:249–84. 2. Nakashima K, Taga T. gp130 And the IL-6 family of cytokines: signa-ling mechanisms and thrombopoietic activities. Semin Hematol 1998; 35:210–21 | spa |
dc.relation.references | Taupin JL, Pitard V, Dechanet J, Miossec V, Gualde N, Moreau JF. Leukemia inhibitory factor: part of a large in-gathering family. Int Rev Immunol 1998; 16:397–426 | spa |
dc.relation.references | Diveu C, Lak-Hal AHL, Froger J, Ravon E, Grimaud L. Barbier F, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for Interleukin-31 signaling. Eur Cytokyne Netw 2004; 15: 291-302 | spa |
dc.relation.references | Liu KD, Gaffen SL, Goldsmith MA. Jak/STAT signa-ling by cytokine receptors. Curr Opin Immunol 1998; 10:271–8 | spa |
dc.relation.references | Zhang JG, Zhang Y, Owczarek CM, Ward LD, Moritz RL, Simpson RJ, et al. Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor -chain in normal human urine and plasma. J Biol Chem 1998; 273:10798–805 | spa |
dc.relation.references | Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998; 273: 19925–8 | spa |
dc.relation.references | Argetsinger LS, Norstedt G, Billestrup N, White MF, Carter-Su C. Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signaling. J Biol Chem 1996; 271:29415–21 | spa |
dc.relation.references | Oh H, Fujio Y, Kunisada K, Hirota H, Matsui H, Kishimo-to T, et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J Biol Chem 1998; 273:9703–10 | spa |
dc.relation.references | Ernst M, Gearing DP, Dunn AR. Functional and bio-chemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells. EMBO J 1994; 13:1574–84 | spa |
dc.relation.references | Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, et al. Cloning and characteriza-tion of novel CIS family genes. Biochem Biophys Res Commun 1997; 239:439–46 | spa |
dc.relation.references | Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 1998; 95:10626–31 | spa |
dc.relation.references | Gibson RM, Laszlo GS, Nathanson NM. Calmodulin-dependent protein kinases phosphorylate gp130 at the serine-based dileucine internalization motif. Biochim Biophys Acta 2005;1714:56-62 | spa |
dc.relation.references | Auernhammer AC, Melmed S. Leukemia-Inhibitory Fac-tor—Neuroimmune Modulator of Endocrine Function. Endocr Rev 2000; 21: 313-45 | spa |
dc.relation.references | Tomida M, Saito T. The human hepatocyte growth factor (HGF) gene is transcriptionally activated by leukemia inhibitory factor through the Stat binding element. On-cogene 2004; 23:679-86. | spa |
dc.contributor.cvlac | García Cardona, Ananías [0001665406] | spa |
dc.contributor.googlescholar | García Cardona, Ananías [2VOuDIMAAAAJ&hl=es&oi=ao] | spa |
dc.contributor.orcid | García Cardona, Ananías [0000-0002-0202-8950] | spa |
dc.subject.lemb | Ciencias médicas | spa |
dc.subject.lemb | Ciencias de la salud | spa |
dc.subject.lemb | Medicina | spa |
dc.identifier.repourl | repourl:https://repository.unab.edu.co | |
dc.description.abstractenglish | El Factor Inhibidor de la Leucemia (LIF), es un mediador de co-municación celular con un amplio rango de actividades biológicas que incluyen diferenciación celular, crecimiento y proliferación celular, trofismo celular y efecto anti-apoptótico protección celular de diferentes tipos de células y tejidos, regulación del metabolismo energético y óseo, desarrollo neural, embriogénesis, reparación y remodelación tisular, modulación de la inflamación. Debido a sus actividades pleiotrópicas, es central en los eventos patológicos, relacionados a muchos desórdenes. En esta revisión se comentaran los diversos tópicos relacionados con esta citoquina. [García GA, Mejía O, García A, Clavijo D, Muñoz J, Hernández S. Factor Inhibidor de la Leucemia y su papel en procesos fisiológicos y patológicos. MedUNAB 2006 | eng |
dc.subject.proposal | Cáncer | spa |
dc.subject.proposal | Citoquina | spa |
dc.subject.proposal | Embriología | spa |
dc.subject.proposal | Factor de crecimiento | spa |
dc.subject.proposal | Infertilidad | spa |
dc.subject.proposal | Interleukina 6 | spa |
dc.subject.proposal | Neurogenesis | spa |
dc.type.redcol | http://purl.org/redcol/resource_type/ART | |
dc.rights.creativecommons | Atribución-NoComercial-SinDerivadas 2.5 Colombia | * |